 Niranjan Manoharan
Concepts (154)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Retinopathy | 7 | 2026 | 210 | 3.310 |
Why?
| | Geographic Atrophy | 10 | 2026 | 97 | 1.780 |
Why?
| | Retinal Diseases | 2 | 2025 | 101 | 1.580 |
Why?
| | Retinal Detachment | 3 | 2022 | 73 | 1.390 |
Why?
| | Tomography, Optical Coherence | 12 | 2026 | 270 | 1.360 |
Why?
| | Vitreoretinopathy, Proliferative | 2 | 2022 | 15 | 1.350 |
Why?
| | Fluorescein Angiography | 10 | 2026 | 189 | 1.230 |
Why?
| | Macular Degeneration | 8 | 2025 | 191 | 1.230 |
Why?
| | Vitreous Body | 4 | 2022 | 117 | 1.030 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2025 | 39 | 0.910 |
Why?
| | Diabetes Mellitus | 2 | 2024 | 1101 | 0.860 |
Why?
| | Macular Edema | 2 | 2026 | 49 | 0.820 |
Why?
| | Cataract | 2 | 2023 | 238 | 0.760 |
Why?
| | Insulins | 1 | 2023 | 39 | 0.750 |
Why?
| | Vitreous Detachment | 1 | 2022 | 6 | 0.750 |
Why?
| | Ophthalmology | 1 | 2023 | 120 | 0.700 |
Why?
| | Complement System Proteins | 3 | 2025 | 314 | 0.690 |
Why?
| | Visual Acuity | 12 | 2026 | 490 | 0.650 |
Why?
| | Protein Kinase Inhibitors | 1 | 2025 | 981 | 0.580 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2023 | 2602 | 0.570 |
Why?
| | Lens Implantation, Intraocular | 2 | 2018 | 80 | 0.550 |
Why?
| | Registries | 7 | 2025 | 2410 | 0.550 |
Why?
| | Glaucoma, Angle-Closure | 1 | 2018 | 23 | 0.540 |
Why?
| | Glaucoma, Open-Angle | 1 | 2018 | 104 | 0.490 |
Why?
| | Phacoemulsification | 1 | 2018 | 123 | 0.480 |
Why?
| | Wet Macular Degeneration | 3 | 2025 | 58 | 0.470 |
Why?
| | Choroid | 2 | 2025 | 80 | 0.420 |
Why?
| | Biomarkers | 7 | 2025 | 4302 | 0.410 |
Why?
| | Antineoplastic Agents | 1 | 2025 | 2219 | 0.410 |
Why?
| | Multimodal Imaging | 2 | 2025 | 129 | 0.390 |
Why?
| | Vitrectomy | 3 | 2022 | 73 | 0.370 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2026 | 783 | 0.340 |
Why?
| | Epiretinal Membrane | 2 | 2020 | 7 | 0.330 |
Why?
| | Retrospective Studies | 11 | 2025 | 17330 | 0.330 |
Why?
| | Retinal Perforations | 2 | 2020 | 18 | 0.320 |
Why?
| | Central Nervous System Neoplasms | 1 | 2012 | 177 | 0.300 |
Why?
| | Aged | 17 | 2026 | 26217 | 0.280 |
Why?
| | Aged, 80 and over | 9 | 2025 | 8347 | 0.280 |
Why?
| | Humans | 34 | 2026 | 145783 | 0.270 |
Why?
| | Follow-Up Studies | 10 | 2025 | 5428 | 0.240 |
Why?
| | Uveitis, Anterior | 1 | 2026 | 27 | 0.230 |
Why?
| | Fovea Centralis | 1 | 2025 | 24 | 0.230 |
Why?
| | Complement Activation | 2 | 2025 | 399 | 0.230 |
Why?
| | Optical Imaging | 1 | 2026 | 62 | 0.220 |
Why?
| | Fundus Oculi | 4 | 2026 | 89 | 0.220 |
Why?
| | Ocular Hypertension | 1 | 2026 | 70 | 0.220 |
Why?
| | Middle Aged | 15 | 2026 | 36309 | 0.220 |
Why?
| | Risk Factors | 7 | 2025 | 10919 | 0.220 |
Why?
| | Retinal Drusen | 1 | 2024 | 31 | 0.200 |
Why?
| | India | 5 | 2024 | 213 | 0.200 |
Why?
| | Hospitals, County | 1 | 2023 | 11 | 0.200 |
Why?
| | Intraocular Pressure | 3 | 2026 | 330 | 0.190 |
Why?
| | Male | 19 | 2026 | 73010 | 0.190 |
Why?
| | Scleral Buckling | 1 | 2022 | 16 | 0.190 |
Why?
| | Retinal Vein Occlusion | 1 | 2022 | 14 | 0.180 |
Why?
| | Retinal Vein | 1 | 2022 | 14 | 0.180 |
Why?
| | Female | 20 | 2026 | 79045 | 0.180 |
Why?
| | Brain Neoplasms | 1 | 2012 | 1331 | 0.180 |
Why?
| | Cluster Analysis | 1 | 2023 | 501 | 0.180 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2024 | 552 | 0.170 |
Why?
| | Esophageal Neoplasms | 1 | 2025 | 348 | 0.170 |
Why?
| | Complement Factor B | 1 | 2022 | 106 | 0.170 |
Why?
| | Retinoschisis | 1 | 2020 | 2 | 0.160 |
Why?
| | Nanopores | 1 | 2020 | 11 | 0.160 |
Why?
| | Membranes, Artificial | 1 | 2020 | 68 | 0.150 |
Why?
| | Machine Learning | 1 | 2026 | 587 | 0.150 |
Why?
| | Retina | 1 | 2022 | 330 | 0.150 |
Why?
| | Neoplasms | 3 | 2024 | 2913 | 0.150 |
Why?
| | Nanotechnology | 1 | 2020 | 114 | 0.150 |
Why?
| | Eye Diseases, Hereditary | 1 | 2018 | 15 | 0.140 |
Why?
| | Axial Length, Eye | 1 | 2018 | 16 | 0.140 |
Why?
| | Exfoliation Syndrome | 1 | 2018 | 10 | 0.140 |
Why?
| | Corneal Pachymetry | 1 | 2018 | 16 | 0.140 |
Why?
| | Adenocarcinoma | 1 | 2025 | 926 | 0.140 |
Why?
| | Pseudophakia | 1 | 2018 | 21 | 0.140 |
Why?
| | Internet | 1 | 2023 | 693 | 0.130 |
Why?
| | Refraction, Ocular | 1 | 2018 | 47 | 0.130 |
Why?
| | Medicare | 1 | 2024 | 904 | 0.130 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 849 | 0.130 |
Why?
| | Trabeculectomy | 1 | 2018 | 75 | 0.130 |
Why?
| | Delivery of Health Care | 1 | 2024 | 948 | 0.120 |
Why?
| | Adult | 8 | 2025 | 40881 | 0.120 |
Why?
| | Lenses, Intraocular | 1 | 1996 | 49 | 0.120 |
Why?
| | Cross-Sectional Studies | 5 | 2025 | 5925 | 0.110 |
Why?
| | Incidence | 4 | 2024 | 2934 | 0.110 |
Why?
| | Retinal Pigment Epithelium | 2 | 2024 | 79 | 0.100 |
Why?
| | Tobacco Smoke Pollution | 1 | 2016 | 227 | 0.100 |
Why?
| | Glaucoma | 1 | 1996 | 251 | 0.100 |
Why?
| | Disease Progression | 3 | 2025 | 2865 | 0.090 |
Why?
| | Metabolomics | 1 | 2018 | 733 | 0.090 |
Why?
| | ras GTPase-Activating Proteins | 1 | 2012 | 14 | 0.090 |
Why?
| | Lymphocyte Subsets | 1 | 2012 | 78 | 0.090 |
Why?
| | Intracellular Space | 1 | 2012 | 64 | 0.090 |
Why?
| | Protein Multimerization | 1 | 2012 | 205 | 0.080 |
Why?
| | Cell Communication | 1 | 2012 | 327 | 0.080 |
Why?
| | Young Adult | 2 | 2019 | 14254 | 0.070 |
Why?
| | Smoking | 1 | 2016 | 1477 | 0.070 |
Why?
| | Algorithms | 2 | 2026 | 1851 | 0.070 |
Why?
| | Adolescent | 2 | 2019 | 22577 | 0.060 |
Why?
| | Prognosis | 3 | 2024 | 4330 | 0.060 |
Why?
| | United States | 1 | 2024 | 16126 | 0.060 |
Why?
| | Intravitreal Injections | 1 | 2026 | 71 | 0.060 |
Why?
| | Cataract Extraction | 2 | 1998 | 120 | 0.060 |
Why?
| | Uncertainty | 1 | 2026 | 146 | 0.060 |
Why?
| | Antibodies, Bispecific | 1 | 2026 | 68 | 0.050 |
Why?
| | Angiogenesis Inhibitors | 1 | 2026 | 239 | 0.050 |
Why?
| | Age Factors | 1 | 2012 | 3346 | 0.050 |
Why?
| | Time Factors | 2 | 2025 | 7134 | 0.050 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2026 | 289 | 0.050 |
Why?
| | Demography | 1 | 2024 | 282 | 0.050 |
Why?
| | Chemokine CCL5 | 1 | 2023 | 40 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2023 | 207 | 0.050 |
Why?
| | Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| | HIV Infections | 1 | 2018 | 3195 | 0.040 |
Why?
| | Prospective Studies | 2 | 2025 | 8078 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2025 | 6085 | 0.040 |
Why?
| | Fibrinogen | 1 | 2022 | 180 | 0.040 |
Why?
| | Vision Disorders | 1 | 2022 | 179 | 0.040 |
Why?
| | Dialysis | 1 | 2020 | 19 | 0.040 |
Why?
| | Adsorption | 1 | 2020 | 153 | 0.040 |
Why?
| | Infant, Newborn | 1 | 2012 | 6465 | 0.040 |
Why?
| | Immunologic Factors | 1 | 2022 | 260 | 0.040 |
Why?
| | Rabbits | 1 | 2020 | 653 | 0.040 |
Why?
| | Xanthine | 1 | 2018 | 7 | 0.030 |
Why?
| | Infant | 1 | 2012 | 10091 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2968 | 0.030 |
Why?
| | Purines | 1 | 2018 | 187 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2018 | 195 | 0.030 |
Why?
| | Child, Preschool | 1 | 2012 | 11868 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 1998 | 157 | 0.030 |
Why?
| | Polymers | 1 | 2020 | 485 | 0.030 |
Why?
| | Mental Health | 1 | 2022 | 796 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2018 | 732 | 0.030 |
Why?
| | Colorado | 1 | 2025 | 4556 | 0.030 |
Why?
| | Metabolome | 1 | 2018 | 391 | 0.030 |
Why?
| | Postoperative Complications | 2 | 1998 | 2977 | 0.030 |
Why?
| | Protein Binding | 1 | 2020 | 2240 | 0.030 |
Why?
| | Phenotype | 1 | 2022 | 3170 | 0.020 |
Why?
| | Glucose | 1 | 2018 | 1049 | 0.020 |
Why?
| | Population Surveillance | 1 | 2016 | 484 | 0.020 |
Why?
| | Inflammation | 1 | 2023 | 2884 | 0.020 |
Why?
| | Child | 1 | 2012 | 22740 | 0.020 |
Why?
| | Protein Interaction Mapping | 1 | 2012 | 105 | 0.020 |
Why?
| | Oxidative Stress | 1 | 2018 | 1360 | 0.020 |
Why?
| | Prevalence | 1 | 2018 | 2875 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 3211 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2012 | 3130 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2012 | 4151 | 0.010 |
Why?
| | Animals | 2 | 2020 | 38101 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 5224 | 0.010 |
Why?
| | Eyeglasses | 1 | 1998 | 24 | 0.010 |
Why?
| | Safety | 1 | 1998 | 358 | 0.010 |
Why?
| | Mice | 1 | 2012 | 18355 | 0.010 |
Why?
| | Treatment Outcome | 1 | 1998 | 11794 | 0.000 |
Why?
|
|
Manoharan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|